Cargando…
Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway
BACKGROUND: Activation of nuclear factor-kappa B (NF-κΒ) through DNA damage is one of the causes of tumor cell resistance to radiotherapy. Chromosome region 1 (CRM1) regulates tumor cell proliferation, drug resistance, and radiation resistance by regulating the nuclear-cytoplasmic translocation of i...
Autores principales: | Liu, Xuejiao, Tu, Yiming, Wang, Yifeng, Zhou, Di, Chong, Yulong, Shi, Lin, Liu, Guanzheng, Zhang, Xu, Wu, Sijin, Li, Huan, Gao, Shangfeng, Niu, Mingshan, Yu, Rutong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106748/ https://www.ncbi.nlm.nih.gov/pubmed/32256206 http://dx.doi.org/10.1186/s12935-020-01186-y |
Ejemplares similares
-
SWAP-70 promotes glioblastoma cellular migration and invasion by regulating the expression of CD44s
por: Shi, Lin, et al.
Publicado: (2019) -
MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activation
por: Liu, Xuejiao, et al.
Publicado: (2020) -
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
por: Liu, Xuejiao, et al.
Publicado: (2016) -
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
por: Liu, Xuejiao, et al.
Publicado: (2015) -
CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells
por: Liu, Xuejiao, et al.
Publicado: (2016)